Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. Zuber, Julien; Frimat, Marie; Caillard, Sophie; Kamar, Nassim; Gatault, Philippe; Petitprez, Florent; Couzi, Lionel; Jourde-Chiche, Noemie; Chatelet, Valérie; Gaisne, Raphael; Bertrand, Dominique; Bamoulid, Jamal; Louis, Magali; Sberro Soussan, Rebecca; Navarro, David; Westeel, Pierre-Francois; Frimat, Luc; Colosio, Charlotte; Thierry, Antoine; Rivalan, Joseph; Albano, Laetitia; Arzouk, Nadia; Cornec-Le Gall, Emilie; Claisse, Guillaume; Elias, Michelle; El Karoui, Khalil; Chauvet, Sophie; Coindre, Jean-Philippe; Rerolle, Jean-Philippe; Tricot, Leila; Sayegh, Johnny; Garrouste, Cyril; Charasse, Christophe; Delmas, Yahsou; Massy, Ziad; Hourmant, Maryvonne; Servais, Aude; Loirat, Chantal; Fakhouri, Fadi; Pouteil-Noble, Claire; Peraldi, Marie-Noelle; Legendre, Christophe; Rondeau, Eric; Le Quintrec, Moglie; Frémeaux-Bacchi, Véronique. Journal of the American Society of Nephrology: JASN. 2019; 30: p.2449-2463. doi:10.1681/ASN.2019040331Article
Épidémiologie clinique